PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31732720-4	2020	Whereas ruxolitinib inhibits Stat5 activation in erythroid progenitor populations, it fails to inhibit this same pathway in HSCs.	ruxolitinib	8-19	signal transducer and activator of transcription 5A	Mus musculus	29-34	
24957147-0	2014	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.	ruxolitinib	40-51	signal transducer and activator of transcription 5A	Mus musculus	5-10	
24957147-4	2014	We demonstrated that the combination of RUX, at clinically achievable concentrations, with the specific and potent tyrosine kinase inhibitor nilotinib, reduced the activity of the JAK2/STAT5 pathway in vitro relative to either single agent alone.	ruxolitinib	40-43	signal transducer and activator of transcription 5A	Mus musculus	185-190	
35352806-6	2022	Jak2 is activated in Nras mutant HSC and progenitors (HSPCs) and inhibiting Jak2 with Ruxolitinib significantly decreases Stat5 activation and HSPC hyper-proliferation in vivo in NrasG12D mice.	ruxolitinib	86-97	signal transducer and activator of transcription 5A	Mus musculus	122-127	
29778097-8	2018	Furthermore, we showed that only two-week treatment of mice with ruxolitinib, a JAK1/2 inhibitor, blocked STAT5 activation, restored apoptosis, and prevented early lesion progression.	ruxolitinib	65-76	signal transducer and activator of transcription 5A	Mus musculus	106-111	
31123029-9	2020	JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and Ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive peripheral T-cell lymphoma development, defining both STAT5 molecules as targets for therapeutic intervention.	ruxolitinib	80-91	signal transducer and activator of transcription 5A	Mus musculus	30-35	
31123029-9	2020	JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and Ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive peripheral T-cell lymphoma development, defining both STAT5 molecules as targets for therapeutic intervention.	ruxolitinib	80-91	signal transducer and activator of transcription 5A	Mus musculus	151-157	
31123029-9	2020	JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and Ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive peripheral T-cell lymphoma development, defining both STAT5 molecules as targets for therapeutic intervention.	ruxolitinib	80-91	signal transducer and activator of transcription 5A	Mus musculus	151-156	
29461617-0	2018	JAK/STAT5 signaling pathway inhibitor ruxolitinib reduces airway inflammation of neutrophilic asthma in mice model.	ruxolitinib	38-49	signal transducer and activator of transcription 5A	Mus musculus	4-9	
29461617-13	2018	CONCLUSIONS: Ruxolitinib may suppress the survival of Th17 cells by inhibiting the JAK/STAT5 signaling pathway and regulate the anti-apoptosis proteins Bcl-2 and Caspase3, thus promoting the increase of Thl7 cells entering the apoptotic pathway and reducing airway inflammation in NA mice.	ruxolitinib	13-24	signal transducer and activator of transcription 5A	Mus musculus	87-92	
25645356-4	2015	Moreover, ETP-ALL showed hyperactivation of STAT5 in response to interleukin-7, an effect that was abrogated by the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	133-144	signal transducer and activator of transcription 5A	Mus musculus	44-49